112 related articles for article (PubMed ID: 2626038)
21. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
22. Non-genomic effects of progestins--inhibition of cell growth and increased intracellular levels of cyclic nucleotides.
Sager G; Ørbo A; Jaeger R; Engström C
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):1-8. PubMed ID: 12648518
[TBL] [Abstract][Full Text] [Related]
23. Effects of antiprogestins RU486 and ZK98299 on the expression of cell cycle proteins of a medroxyprogesterone acetate (MPA)-induced murine mammary tumor.
Peters MG; Vanzulli S; Elizalde PV; Charreau EH; Goin MM
Oncol Rep; 2001; 8(2):445-9. PubMed ID: 11182072
[TBL] [Abstract][Full Text] [Related]
24. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats.
Stoeckemann K; Hegele-Hartung C; Chwalisz K
Hum Reprod; 1995 Dec; 10(12):3264-71. PubMed ID: 8822456
[TBL] [Abstract][Full Text] [Related]
25. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D.
Dannecker C; Possinger K; Classen S
Ann Oncol; 1996 Apr; 7(4):391-5. PubMed ID: 8805931
[TBL] [Abstract][Full Text] [Related]
26. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors.
Bustuoabad OD; di Gianni PD; Franco M; Kordon EC; Vanzulli SI; Meiss RP; Grion LC; Díaz GS; Nosetto SH; Hockl P; Lombardi MG; Pasqualini CD; Ruggiero RA
Oncol Res; 2002; 13(3):147-60. PubMed ID: 12549624
[TBL] [Abstract][Full Text] [Related]
27. Differential response of an ovarian-responsive mouse mammary tumor to androgenic and estrogenic agents.
Matsuzawa A; Ikeda Y
Cancer Res; 1983 Aug; 43(8):3680-6. PubMed ID: 6861137
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats.
Luo S; Stojanovic M; Labrie C; Labrie F
Int J Cancer; 1997 Nov; 73(4):580-6. PubMed ID: 9389575
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
30. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
31. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms.
Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD
Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500
[TBL] [Abstract][Full Text] [Related]
32. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Lee O; Choi MR; Christov K; Ivancic D; Khan SA
Cancer Lett; 2016 Jul; 376(2):310-7. PubMed ID: 27080304
[TBL] [Abstract][Full Text] [Related]
33. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
[TBL] [Abstract][Full Text] [Related]
34. Effect of medroxyprogesterone acetate on the growth of mouse transplanted tumors: relation with hormone sensitivity.
Formelli F; Ronchi E; Di Fronzo G
Anticancer Res; 1985; 5(3):313-9. PubMed ID: 3160299
[TBL] [Abstract][Full Text] [Related]
35. [Effects of progesterone antagonists on the eosinophilic granulocytes in the rat uterus].
Schubert AK
Ann Anat; 1998 Oct; 180(5):401-8. PubMed ID: 9795690
[TBL] [Abstract][Full Text] [Related]
36. Luteal control of endometrial receptivity and its modification by progesterone antagonists.
Hegele-Hartung C; Mootz U; Beier HM
Endocrinology; 1992 Nov; 131(5):2446-60. PubMed ID: 1425442
[TBL] [Abstract][Full Text] [Related]
37. Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland.
Li M; Spitzer E; Zschiesche W; Binas B; Parczyk K; Grosse R
J Cell Physiol; 1995 Jul; 164(1):1-8. PubMed ID: 7790381
[TBL] [Abstract][Full Text] [Related]
38. Enhanced and reversed growth in vitro of a pregnancy-dependent mouse mammary tumor (TPDMT-4) by a gonadotropin-releasing hormone agonist analog.
Matsuzawa A; Yamamoto T
Eur J Cancer Clin Oncol; 1982 May; 18(5):495-505. PubMed ID: 6811279
[TBL] [Abstract][Full Text] [Related]
39. Antiprogestin-progesterone interactions.
Michna H; Fritzemeier KH; Parczyk K; Nishino Y; Schneider MR
Cancer Treat Res; 1996; 83():191-212. PubMed ID: 8826648
[No Abstract] [Full Text] [Related]
40. Importance of progesterone in DNA synthesis of pregnancy-dependent mammary tumors in mice.
Yanai R; Nagasawa H
Int J Cancer; 1976 Sep; 18(3):317-21. PubMed ID: 986372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
